Show simple item record

dc.contributor.authorSohretoglu, Didem
dc.contributor.authorHuang, Shile
dc.date.accessioned2019-12-16T10:09:52Z
dc.date.available2019-12-16T10:09:52Z
dc.date.issued2018
dc.identifier.issn1871-5206
dc.identifier.urihttps://doi.org/10.2174/1871520617666171113121246
dc.identifier.urihttp://hdl.handle.net/11655/19987
dc.description.abstractThe mushroom Ganoderma lucidum (G. lucidum) has been used for centuries in Asian countries to treat various diseases and to promote health and longevity. Clinical studies have shown beneficial effects of G. lucidum as an alternative adjuvant therapy in cancer patients without obvious toxicity. G. lucidum polysaccharides (GLP) is the main bioactive component in the water soluble extracts of this mushroom. Evidence from in vitro and in vivo studies has demonstrated that GLP possesses potential anticancer activity through immunomodulatory, anti-proliferative, pro-apoptotic, anti-metastatic and anti-angiogenic effects. Here, we briefly summarize these anticancer effects of GLP and the underlying mechanisms.
dc.language.isoen
dc.publisherBentham Science Publ Ltd
dc.relation.isversionof10.2174/1871520617666171113121246
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectOncology
dc.subjectPharmacology & Pharmacy
dc.titleGanoderma Lucidum Polysaccharides As An Anti-Cancer Agent
dc.typeinfo:eu-repo/semantics/review
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalAnti-Cancer Agents In Medicinal Chemistry
dc.contributor.departmentFarmakognozi
dc.identifier.volume18
dc.identifier.issue5
dc.identifier.startpage667
dc.identifier.endpage674
dc.description.indexWoS


Files in this item

This item appears in the following Collection(s)

Show simple item record